Effects of proteasome inhibitors on leukemias.
- Author:
Shu-Qing LÜ
1
;
Jian-Min YANG
;
Jian-Min WANG
Author Information
1. Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Boronic Acids;
therapeutic use;
Bortezomib;
Humans;
Leukemia;
drug therapy;
enzymology;
Multiple Myeloma;
drug therapy;
Protease Inhibitors;
therapeutic use;
Proteasome Inhibitors;
Pyrazines;
therapeutic use
- From:
Journal of Experimental Hematology
2007;15(4):896-900
- CountryChina
- Language:Chinese
-
Abstract:
The proteasome is primarily responsible for intracellular protein degradation. The abnormality of its activity is sign of tumorigenesis. It was confirmed that proteasome inhibitors have activities against a variety of malignancies. Bortezomib, the first proteasome inhibitor, obtained permission of clinical trial and on sale. Multiple myeloma patients treated with bortezomib have gained a high overall response rate and complete remission rate. A lot of studies on effects of proteasome inhibitors on leukemias, including plasma cell leukemia; chronic lymphocytic leukemia, adult T cell lymphoma/leukemia, chronic myeloid leukemia and acute myeloid leukemia, were reviewed in this article.
